Next Article in Journal
Thioredoxin and Cancer: A Role for Thioredoxin in all States of Tumor Oxygenation
Next Article in Special Issue
Modulation of Radiation-Induced Genetic Damage by HCMV in Peripheral Blood Lymphocytes from a Brain Tumor Case-Control Study
Previous Article in Journal
Biology of Human Cutaneous Melanoma
Previous Article in Special Issue
Overexpression of Periostin and Lumican in Esophageal Squamous Cell Carcinoma
Article Menu

Export Article

Open AccessReview
Cancers 2010, 2(1), 190-208; doi:10.3390/cancers2010190

Cancer Biomarkers: Are We Ready for the Prime Time?

1
Institute of Cytology and Preventive Oncology, Division of Molecular Oncology, Noida, 201301, UP, India
2
Methods and Technologies Branch, Epidemiology and Genetics Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, National Institues of Health (NIH), 6130 Executive Blvd., Suite 5100, Bethesda, MD 20892-7324, USA
Present address: Lab Molecular Biology, NCI, NIH, Bethesda, MD 20892, USA.
*
Author to whom correspondence should be addressed.
Received: 20 February 2010 / Revised: 2 March 2010 / Accepted: 19 March 2010 / Published: 22 March 2010
(This article belongs to the Special Issue Biomarkers: Oncology Studies)
View Full-Text   |   Download PDF [202 KB, uploaded 22 March 2010]   |  

Abstract

A biomarker is a characteristic that is objectively measured and evaluated as an indicator of normal biologic processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention. In cancer, a biomarker refers to a substance or process that is indicative of the presence of cancer in the body. A biomarker might be either a molecule secreted by a tumor or it can be a specific response of the body to the presence of cancer. Genetic, epigenetic, proteomic, glycomic, and imaging biomarkers can be used for cancer diagnosis, prognosis and epidemiology. These markers can be assayed in non-invasively collected biofluids. However, few cancer biomarkers are highly sensitive and specific for cancer detection at the present time. Consequently, biomarkers are not yet ready for routine use due to challenges in their clinical validation for early disease detection, diagnosis and monitoring to improve long-term survival of patients. View Full-Text
Keywords: biomarker; cancer; diagnosis; glycans; prognosis; validation biomarker; cancer; diagnosis; glycans; prognosis; validation
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Mishra, A.; Verma, M. Cancer Biomarkers: Are We Ready for the Prime Time? Cancers 2010, 2, 190-208.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top